Cocrystal Pharma Faces Cash Crunch with $7.7M on Hand After $8.8M Loss; Norovirus Drug Progresses
COCP sits 15% above its 52-week low of $0.859.
Summary
Cocrystal Pharma reported a 2025 net loss of $8.8 million and an unrestricted cash balance of $7.7 million as of December 31, 2025. Concurrently, the company announced the enrollment of the first subjects in a Phase 1b human challenge study for its norovirus candidate, CDI-988. The reported cash balance is less than the annual net loss, indicating a very short cash runway for this micro-cap biotech, which raises significant concerns about its ability to fund ongoing operations and clinical trials without highly dilutive financing. While the advancement of CDI-988 into Phase 1b is a positive clinical milestone, the precarious financial position overshadows this progress. Additionally, the company noted "trial conduct issues" for its influenza program (CC-42344), which is a negative operational detail. Investors will closely monitor the company's cash burn rate and any potential financing activities, as well as updates on the CDI-988 Phase 1b study.
At the time of this announcement, COCP was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.86 to $2.67. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.